Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

Based on its latest expense profile and business plan, after cutting its staff, Recursion said it now expects its projected cash runway to extend into the fourth quarter of 2027. Recursion will pay ...

Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

The MIT model predicts molecular binding affinity at newfound speed and accuracy, offering a powerful tool for commercial drug discovery.

Key Takeaways Top YouTube channels offer beginner-to-advanced DSA tutorials for all skill levels.Expert-led content helps ace ...

Cardiovascular diseases cause one death every 33 seconds in America. Diagnosing these conditions, which account for ...